NCT07142421View on ClinicalTrials.gov

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

December 30, 2027

Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
DRUG

Combination therapy (COMB)

Trifluridine/tipiracil combined with Anlotinib in treatment

Trial Locations (1)

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

First Affiliated Hospital of Zhejiang University

OTHER